A biopharmaceutical company developing therapeutic products principally based on third-generation NEUGENE antisense technology.


Updates from The Motley Fool

Latest updates on Sarepta Therapeutics from Fool.com.  The Fool has written over 300 articles on Sarepta Therapeutics.
4 Stocks I'd Avoid at All Costs

Whether you're interested in these biotech stocks or not, there are some important lessons to be ...

3 Stocks to Avoid in Biotech

Buying biotech stocks has always been a risky business, but these three are best left on the shelf.



Stock Performance

View Interactive SRPT Charts
Sponsored by

Key Data Points

Primary metrics and data points about Sarepta Therapeutics.
Current Price: $33.77
Prev Close: $33.86
Open: $35.00
Bid: $33.69
Ask: $33.75
Day's Range: $33.63 - $35.35
52wk Range: $17.64 - $63.73
Volume: 1,310,268
Avg Vol 1,670,709
Market Cap: $2B
P/E (ttm): -12.63
EPS (ttm): ($2.68)
Div & Yield: $0.00 (0.0%)

Company Rating

What our community thinks about Sarepta Therapeutics.
CAPS Rating 2 out of 5
 
285 Outperform
53 Underperform
CAPS All Stars
 
50 Outperform
14 Underperform

How do you think Sarepta Therapeutics will perform against the market?



You pick for Sarepta Therapeutics is winning

Score: +97.74
Call: Outperform
Time Frame: Five Plus Years
Start Price: $18.24
Start Date: 3/29/2007
Gain/Loss: +$152.4%
S&P Gain/Loss: +$54.7%

Powered by Motley Fool CAPS


Business Summary

Industry, sector and description for Sarepta Therapeutics.

A biopharmaceutical company developing therapeutic products principally based on third-generation NEUGENE antisense technology.

  • Exchange: NASDAQ
  • Sector: Healthcare
  • Industry: Drug Makers